🧠 Anxiolytic Peptide

Selank (5 mg Vial) Dosage Protocol

Selank is a synthetic heptapeptide based on the tuftsin sequence (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension for stability. Developed at the Institute of Molecular Genetics in Russia, it is approved there as an anxiolytic with nootropic properties. Studied for anxiety reduction, stress modulation, immune support, and enkephalin system regulation.

⚡ Quickstart Highlights

Reconstitution

1.0 mL BAC water → 5.0 mg/mL (intranasal), or dilute

Daily Range

250–3000 mcg via intranasal

Route

Intranasal (primary)

Half-life

~1–2 minutes; CNS effects last hours

Dosing & Reconstitution Guide

Route: Intranasal (primary) or subcutaneous | Frequency: 1–3× daily

Phase	Daily Dose	Notes
Starting	250–500 mcg/day	2–4 intranasal drops total; assess response
Standard	1000–1500 mcg/day	Split into 2–3 applications
Advanced	2000–3000 mcg/day	Upper range from approved protocols

Selank is non-sedating and non-habit-forming, which distinguishes it from benzodiazepine anxiolytics. It modulates GABA-A receptor sensitivity without direct binding, producing anxiolytic effects without dependence risk. Can be used in morning or daytime dosing without sedation.

Reconstitution Steps

Draw 1.0 mL bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the vial; avoid foaming.
Gently swirl until dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item	4-Week Cycle	8-Week Cycle
Selank vials (5 mg)	1–2 vials	3–4 vials
Intranasal dropper/spray	1	1–2
Bacteriostatic water (10 mL)	1 × 10 mL	1 × 10 mL

Mechanism of Action

Selank is structurally based on tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunostimulatory tetrapeptide derived from the Fc region of IgG, with a Pro-Gly-Pro C-terminal extension that provides enzymatic stability. Its primary anxiolytic mechanism appears to involve indirect modulation of GABA-A receptor sensitivity — increasing inhibitory neurotransmission without directly binding the benzodiazepine receptor site, explaining the absence of addiction potential or tolerance development.

Additional mechanisms under study include: regulation of enkephalin-degrading enzymes (increasing endogenous enkephalin availability); modulation of serotonin, dopamine, and noradrenergic system activity; upregulation of BDNF; and immunomodulatory effects including upregulation of IL-6, IL-1β, and interferon regulatory factors. The intranasal route is preferred for CNS access.

Research Findings & Safety Profile

Approved anxiolytic in Russia; extensively used in clinical practice for anxiety and stress disorders.
Non-sedating and non-habit-forming — no benzodiazepine-like dependence or tolerance reported.
Modulates GABA-A receptor sensitivity and enkephalin system — anxiolytic without direct GABA binding.
Immunomodulatory: regulates IL-6, IL-1β, and interferon pathways — tuftsin backbone's immune-active heritage.
Well-tolerated with minimal adverse effects in approved clinical use; mild nasal irritation possible.
Some protocols combine Selank (anxiolytic) with Semax (cognitive/stimulant) for balanced neuromodulation.

Storage

State	Temperature	Duration	Notes
Lyophilized	−20°C (−4°F)	Up to 24 months	Dry, dark conditions
Reconstituted	2–8°C (35–46°F)	Up to 28 days	Avoid freeze-thaw; protect from light

⚠ Research Use Only: Selank is approved in Russia; not FDA approved. Intranasal delivery is preferred for CNS effects. Non-habit-forming — does not produce benzodiazepine-like dependence.

References

Semenova TP et al. 'Effect of selank on anxiety level in rats with different phenotypes of emotional-stress reactivity' — Bull Exp Biol Med, 2010 View source ↗

Uchakina ON et al. 'Immunomodulatory effects of selank in patients with anxiety-asthenic disorders' — Zh Nevrol Psikhiatr Im S S Korsakova, 2008